Elevated c-myc messenger RNA in multiple myeloma cell lines.
Oncogene analyses of four human myeloma cell lines provided no indication of gene amplification or rearrangement using DNA probes for the met, raf, abl, mos, erb B, Her-2-neu, fos, myb-7, fms, L-myc, sis, and myb-1 genes. However, a consistent elevation of up to 23-fold in the level of c-myc mRNA was observed in all of the cell lines studied. No restriction fragment length polymorphism (in exons one, two, or three) or c-myc gene amplification has as yet been demonstrated to account for the c-myc mRNA elevation. The c-myc mRNA has a half-life of 25 min which is comparable to that observed in other systems. The elevation in c-myc mRNA is further evidence for the role of the c-myc proto-oncogene in the pathogenesis of myeloma.
Fourney
R
R
Department of Medicine, Cross Cancer Institute, Edmonton, Alberta, Canada.
Palmer
M
M
Ng
A
A
Dietrich
K
K
Belch
A
A
Paterson
M
M
Brox
L
L
D015342:DNA Probes; D005784:Gene Amplification; D015972:Gene Expression Regulation, Neoplastic; D015321:Gene Rearrangement; D006207:Half-Life; D006801:Humans; D007143:Immunoglobulin Heavy Chains / Q000235:genetics; D009101:Multiple Myeloma / Q000235:genetics / Q000473:pathology*; D009194:Myeloma Proteins / Q000096:biosynthesis / Q000235:genetics; D009363:Neoplasm Proteins / Q000096:biosynthesis / Q000235:genetics*; D009857:Oncogenes; D012150:Polymorphism, Restriction Fragment Length; D000090063:Proto-Oncogene Mas; D016271:Proto-Oncogene Proteins c-myc / Q000096:biosynthesis / Q000235:genetics*; D011519:Proto-Oncogenes; D012333:RNA, Messenger / Q000032:analysis*; D012334:RNA, Neoplasm / Q000032:analysis*; D014407:Tumor Cells, Cultured / Q000737:chemistry
D015342:DNA Probes; D007143:Immunoglobulin Heavy Chains; C000715470:MAS1 protein, human; D009194:Myeloma Proteins; D009363:Neoplasm Proteins; D000090063:Proto-Oncogene Mas; D016271:Proto-Oncogene Proteins c-myc; D012333:RNA, Messenger; D012334:RNA, Neoplasm